Infographic
Cell and gene therapy (CGT) broadly refers to the various cell, gene, and RNA-based approaches scientists have developed to specifically target drivers of disease. While the first CGT clinical trials took place at the end of the 20th century, CGT therapeutic development did not accelerate until the late 2010s — powered by the advent of CRISPR/Cas gene editing technologies. Today, there are 48 FDA-approved CGT products targeting diseases such as cancer, HIV, and sickle cell disease, and scientists are developing and trialing thousands of CGT approaches, covering every major organ and body system.
Download this infographic to learn more about:
- CRISPR’s role in advancing CGT approaches
- New technologies for creating tools and models for CGT development
- How scientists are standardizing data to accelerate CGT advances
Offered Free by: Logos Biosystems |. Biocompare
See All Resources from: Logos Biosystems |. Biocompare
